Nanobiotix begins patient dosing in new randomized phase 2 …
2 days ago · Nanobiotix, a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and …
Lilly's Omvoh receives US FDA approval to treat Crohn's disease in …
Jan 17, 2025 · Lilly's Omvoh receives US FDA approval to treat Crohn's disease in adults: Indianapolis Friday, January 17, 2025, 12:00 Hrs [IST] Eli Lilly and Company announced that …
Six start-ups bestowed with new ‘heart of pharma’ at Pharmapack …
22 hours ago · Pharmapack Europe 2025 taking place from January 22 to 23, has selected six start-ups from its 26 strong field of innovators to receive the Pharmapack Europe ‘heart of …
Amgen receives US FDA approval for Lumakras in combo with …
4 days ago · Amgen announced that the US Food and Drug Administration (FDA) has approved Lumakras (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult …
Daiichi Sankyo & AstraZeneca’s Datroway gets US FDA approval …
4 days ago · Daiichi Sankyo & AstraZeneca’s Datroway gets US FDA approval for patients with previously treated metastatic HR positive, HER2 negative breast cancer
Frequency: Weekly (Goes into printing every Tuesday; On stands …
Launched on 21 December 2000, Chronicle Pharmabiz is the No. 1 Pharma news weekly in the South Asian markets; with a target readership that includes 100% coverage of top and middle …
News - Pharmabiz.com
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, …
India's most comprehensive portal on pharmaceutical News, …
Pharmabiz.com - India's most comprehensive online pharma news service. It provides updates on Indian pharma industry, allied sectors like hospitals & diagnostic services,pharma tenders, …
Lilly's mirikizumab is first and only IL23p19 antagonist to report …
Oct 29, 2024 · Lilly's mirikizumab is first and only IL23p19 antagonist to report long-term, multi-year, sustained efficacy and safety data for both UC & Crohn's disease
Pfizer’s Hympavzi receives US FDA approval to treat adults and ...
Oct 14, 2024 · Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST]